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ABSTRACT
Hepatic veno-occlusive disease (HVOD) is a serious life-threatening complication of hematopoietic stem cell
transplantation (HSCT). Currently, there is no optimal therapeutic strategy and preventive measures are
ill-defined. Ursodeoxycholic acid (UA) is well-tolerated oral medication that has been associated with possible
benefit as a prophylactic agent. We sought to summarize and quantify the clinical effects of prophylactic UA
in the context of HSCT.We undertook a systematic review of studies addressing the use of UA as monotherapy
or in combination with other agents in patients undergoing HSCT. The Search Strategy included MEDLINE
(1966 to fourth week of March 2006), EMBASE (1980 to fourth week of March 2006), all EBM Reviews (fourth
quarter of 2005), Ovid Healthstar (1966 to fourth week of March 2006), and Google Scholar on March 20,
2006. Six studies, 4 randomized clinical trials and 2 historically controlled studies, representing 824 patients
were included in the review. Three randomized clinical trials comparing prophylactic UA with no treatment
demonstrated reduced proportion of HVOD (relative risk [RR], 0.34; 95% confidence interval [CI], 0.17-0.66).
When the analysis was limited to higher-quality studies, the beneficial effect of UA remained significant (RR,
0.36; 95% CI, 0.15-0.90). Transplant-related mortality was also reduced with the prophylactic use of UA (RR,
0.58; 95% CI, 0.35-0.95). UA did not significantly attenuate the outcomes of acute graft-versus-host disease
(RR, 0.76; 95% CI, 0.53-1.09), relapse (RR, 0.77; 95% CI, 0.46-1.31), or overall survival (RR, 1.22; 95 % CI,
0.96-1.54). UA appears effective for HVOD prophylaxis in patients undergoing HSCT and should be consid-
ered as a prevention strategy by HSCT centers to reduce HVOD.
© 2007 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
s a common therapy in the management of hemato-
ogic malignancies [1]. Preparative regimens often in-
olve the use of myeloablative chemotherapy with or
ithout total body irradiation, which can contribute
o profound endothelial injury and the development of
epatic veno-occlusive disease (HVOD), also known
s hepatic sinusoidal obstruction syndrome. HVOD h
06emains a major contributor to transplant-related tox-
city and mortality, with incidence rates reported as
igh as 50% in some series and mortality rates that
an approach 50% [2,3].
HVOD is characterized by tender hepatomegaly,
aundice, and ascites [4]. If left untreated, HVOD can
ead to cardiopulmonary compromise, liver failure,
nd death. HVOD is thought to occur as a result of
epatic venous endothelial injury, leading to occlusion
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se of hepatotoxic drugs in the setting of HSCT can
ugment the severity of liver dysfunction in HVOD.
everal risk factors for HVOD have been identiﬁed
nd include a history of liver disease, increased aspar-
ate aminotransferase levels before transplantation,
ecreased pseudocholinesterase levels, use of HLA-
ismatched donors, and previous abdominal irradia-
ion [5,6].
The diagnosis of HVOD is most often made clin-
cally because histologic examination is infrequently
ought due to concerns related to hemostatic control
n these patients. The Seattle [7] or Baltimore [8]
riteria are clinical criteria used to aid in the diagnosis
f HVOD. Using a histologic diagnosis as “gold stan-
ard,” Carrreras et al [9] showed that, although the
peciﬁcity of the Seattle criteria may be as high as
2%, its sensitivity may be as low as 56% even if all 3
riteria are satisﬁed. The more stringent Baltimore
riteria performs as well as the Seattle criteria but
elects a group of patients with more severe HVOD
nd a poorer prognosis [10]. To complicate matters,
he diagnosis of HVOD may not be obvious and may
e confounded by multiple competing diagnoses such
s hepatic graft-versus-host disease (GVHD) [11,12].
The successful management of HVOD involves
reventive measures and/or treatment of the disease.
hen feasible, hepatotoxic medications should be
voided or minimized and prior liver disease opti-
ized before transplantation. However, no therapy
as been shown to be satisfactory in the treatment of
stablished HVOD. Prevention strategies and phar-
acologic prophylaxis are critical to reduce morbidity
nd mortality from HVOD. Several candidate phar-
acologic agents have been reported to be useful,
ncluding ursodeoxycholic acid (UA), heparin mole-
ules [13], prostaglandins [14], glutamine [15], and
eﬁbrotide [16]. The relative beneﬁts and safety of
hese agents remain unclear, leading to various center-
ependent management strategies.
UA occurs naturally in bile and has an important
ole in controlling the concentration of cholesterol in
he blood. It constitutes 5% of naturally occurring
ile acids and can be increased to 50% with oral
dministration [17]. UA is a hydrophilic bile acid and
s used for the dissolution of gallstones [18] and in the
anagement of primary biliary cirrhosis [19-21]. It is
elieved that the retention of endogenous hydropho-
ic bile acids contributes to hepatocellular injury in
atients with cholestatic liver disease. UA appears to
lter the milieu of bile acids by making them less
ydrophobic, resulting in decreased hepatotoxicity
22]. Moreover, additional evidence has suggested that
A may attenuate the pro-inﬂammatory cytokine en-
ironment through decreased expression of tumor ne-
rosis factor , interleukins 1 and 2, and interferon  t23], thereby minimizing endothelial injury occurring
n HSCT associated with the “cytokine storm.”
In the context of HSCT, UA has been used as
rophylaxis and treatment for HVOD and GVHD. In
he earliest studies describing its use in transplanta-
ion, UA was used in the management of chronic
VHD, with evidence that it can normalize liver
unction tests [24-26]. Likewise, early studies in the
reatment of HVOD showed promise and resulted in
everal larger studies exploring its role in HSCT [27-
0]. Notably, the Nordic Bone Marrow Transplanta-
ion group in a randomized study of 200 patients
emonstrated beneﬁcial effects of prophylactic UA in
educing the proportion of patients with transaminitis,
yperbilirubinemia and a trend toward a reduction in
cute GVHD [31]. However, they were not able to
emonstrate decreases in clinical outcomes such as
VOD. Subsequent studies have focused on the use of
A in the prevention of HVOD and several randomized
tudies have been performed. No clear consensus exists
n the role of UA in preventing HVOD despite these
tudies and no common approach has been universally
dopted by HSCT centers.
Given the potential beneﬁts of UA that are par-
icular to HSCT and the current lack of consensus
egarding pharmacologic prophylaxis of HVOD, we
onducted a systematic review of the published liter-
ture to summarize and quantify the clinical effects of
he prophylactic use of UA in patients undergoing
SCT.
ETHODS
A systematic literature search strategy was used to
dentify potential trials on MEDLINE (1966 to fourth
eek of March 2006), EMBASE [16] (1980 to fourth
eek of March 2006), all EBM Reviews (fourth quar-
er of 2005), and Ovid Healthstar (1966 to fourth
eek of March 2006). A search of “gray literature” was
lso performed using Google Scholar. The systematic
earch strategy is documented in Table 1. Studies
elevant to animals but not to humans were excluded.
ublished studies in any language were included. Ax-
an Pharma (Canadian manufacturer of UA) was con-
acted to identify any additional relevant articles/trials
hat were not cited in the previous search. Similarly,
ocal bone marrow transplantation physicians were ap-
roached to identify any other relevant trials/articles.
eferences of selected articles were examined by 2
eviewers (JT and DA) to identify relevant citations.
Using a structured question format (PICOS) to
id our literature search strategy [32], we identiﬁed
rials that satisﬁed the following inclusion criteria:
ontrolled clinical trials, patients undergoing HSCT,
atients receiving UA prophylaxis, use of a compara-
or arm, studies reporting clinical outcomes (HVOD
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J. Tay et al.208r VOD), overall survival (OS), transplant-related
ortality (TRM), GVHD. Publications in any lan-
uage, conference proceedings, abstracts, or journals
ere included in our review. Clinically important out-
able 1. Medline Search Strategy
1. ursodeoxycholic acid.mp. [mpti, ot, ab, nm, hw]
2. ursodiol.mp. [mpti, ot, ab, nm, hw]
3. ursofalk.mp. [mpti, ot, ab, nm, hw]
4. actigall.mp.
5. UDCA.mp.
6. URSO.mp.
7. URSO 250.mp.
8. deoxycholic acid.mp.
9. destolit.mp.
0. urdox.mp.
1. ursogal.mp.
2. hematopoietic stem cell transplant$.mp. [mpti, ot, ab,
nm, hw]
3. hematopoietic peripheral blood stem cell transplant$.mp.
[mpti, ot, ab, nm, hw]
4. haematopoietic stem cell transplant$.mp. [mpti, ot, ab,
nm, hw]
5. haematopoietic peripheral blood stem cell transplant$.mp.
[mpti, ot, ab, nm, hw]
6. peripheral blood cell transplant$.mp. [mpti, ot, ab, nm,
hw]
7. peripheral blood stem cell transplant$.mp. [mpti, ot, ab,
nm, hw]
8. stem cell transplant$.mp. [mpti, ot, ab, nm, hw]
9. bone marrow transplant$.mp. [mpti, ot, ab, nm, hw]
0. marrow transplant$.mp. [mpti, ot, ab, nm, hw]
1. peripheral stem cell transplant$.mp. [mpti, ot, ab,
nm, hw]
2. blood transplant$.mp. [mpti, ot, ab, nm, hw]
3. peripheral blood progenitor cell transplant$.mp. [mpti, ot,
ab, nm, hw]
4. progenitor cell transplant$.mp. [mpti, ot, ab, nm, hw]
5. HSCT.mp. [mpti, ot, ab, nm, hw]
6. SCT.mp. [mpti, ot, ab, nm, hw]
7. PBPCT.mp. [mpti, ot, ab, nm, hw]
8. BMT.mp. [mpti, ot, ab, nm, hw]
9. veno occlusive disease.mp. [mpti, ot, ab, nm, hw]
0. VOD.mp. [mpti, ot, ab, nm, hw]
1. Sinusoidal Obstruction.mp. [mpti, ot, ab, nm, hw]
2. SOS.mp [mpti, ot, ab, nm, hw]
3. Sinusoidal Obstruction Syndrome [mpti, ot, ab, nm, hw]
4. Rokitansky’s Disease.mp. [mpti, ot, ab, nm, hw]
5. Budd’s Syndrome.mp. [mpti, ot, ab, nm, hw]
6. Chiari’s Disease.mp. [mpti, ot, ab, nm, hw]
7. Budd Chiari Syndrome.mp. [mpti, ot, ab, nm, hw]
8. Chiari Budd Syndrome.mp. [mpti, ot, ab, nm, hw]
9. Graft versus host disease.mp. [mpti, ot, ab, nm, hw]
0. graft vs host disease.mp. [mpti, ot, ab, nm, hw]
1. GVH$.mp. [mpti, ot, ab, nm, hw]
2. Runt Disease.mp. [mpti, ot, ab, nm, hw]
3. Homologous Wasting Disease.mp. [mpti, ot, ab, nm, hw]
4. runting disease.mp. [mpti, ot, ab, nm, hw]
5. or/1-11
6. or/12-28
7. or/29-38
8. or/39-44
9. or/46-48
0. 45 and 49omes deﬁned for this review are HVOD, GVHD, cnd mortality. Studies that only reported results of
iochemical tests were excluded from our review.
The deﬁnition of HVOD was deﬁned as weight
ain or ﬂuid accumulation, elevated bilirubin, and
bdominal pain. TRMwas deﬁned as death within 100
ays of HSCT and OS as survival 100 days.
Two reviewers independently applied the inclu-
ion criteria to the identiﬁed articles from the initial
earch strategy. Articles for potential full review were
iscussed between the 2 reviewers. Any discrepancies
ere noted and the decision to include/exclude the
rticle(s) was adjudicated by a third party (DF).
Two reviewers (JT and DA) assessed trial quality
nd extracted the data using a standardized data ab-
traction form. Any discrepancies were documented,
iscussed, and adjudicated by a third party (DF). The
ethodologic quality of randomized studies was eval-
ated by 2 reviewers (JT and DA) using a validated
-point system as proposed by Jadad et al [33]. This
alidated scale demonstrates good inter-rater reliabil-
ty and its components consist of description of study
eing randomized, study described as double blind,
escription of dropouts and withdrawals, and a thor-
ugh description of randomization and blinding. A
uality score 3 was considered high quality. Trial
uality was further assessed with the use of standard-
zed questions related to trial methodology such as
llocation concealment [34].
Relative risk (RR) was used as the primary sum-
ary measurement with 95% conﬁdence intervals
CIs). Pooled measurements were calculated for ran-
omized clinical trials using a random effects model.
ndividual trial estimates and pooled estimates were
erformed with Review Manager software (Cochrane
ollaboration’s Information Management System).
he Cochrane Q/chi-square test and I2 statistic were
lso calculated to evaluate consistency.
ESULTS
In total, 161 articles were identiﬁed by the system-
tic search of the literature and 13 articles were
eemed potentially eligible. Seven of these studies
ere excluded from the review. Four studies were
bstracts of articles included in the review
29,30,35,36]. One study did not use a comparator
roup [37]. One study investigated the treatment of
VOD [28] and 1 study looked at biochemical surro-
ate outcome only [26].
Subsequently, 6 articles met our inclusion crite-
ia (Figure 1). There were no discrepancies between
he 2 reviewers with regard to studies for inclusion.
f the 6 clinical trials included in this review
22,27,31,38-40], 1 clinical trial speciﬁcally evalu-
ted a pediatric population [40], and the other 5 were
onducted in adults [22,27,31,38,39]. Two studies in-
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ransplantation [38,39]. The remaining 4 studies focused
n patients undergoing allogeneic transplantation only
22,27,31,40]. Four of the 6 clinical trials were random-
zed [22,31,38,39], with the remaining 2 using historical
ontrols [27,40]. No randomized study received a score
3 on the Jadad scale. Only 1 of the 4 randomized
tudies reported on allocation concealment [22] and only
study was double blinded [22]. (Table 2).
There were 824 patients from all studies included for
nalysis, with a median sample of 149 patients (range,
9-242 patients). Four studies compared UA with no
reatment [22,27,31,38], 1 study compared combina-
ion therapy (including UA) with no treatment [40],
nd 1 study compared combination therapy using hep-
rin and UA with heparin alone [39]. The baseline
haracteristics were similar apart from age addressed
n the pediatric trial. Important baseline characteris-
ics and risk factors for HVOD are presented in Ta-
les 3 and 4. The deﬁnitions of HVOD used in the
trials were relatively similar when using the Seat-
le criteria, Baltimore criteria, or a variant of the 2
riteria (Table 5).
All 6 trials reported on the primary outcome of
nterest: proportion of patients with HVOD. Four
Figure 1. Flow diagram summarizing the identiﬁcation proctudies reported TRM [22,27,31,39], 3 studies re- oorted OS [31,38,40], and 4 studies reported rates of
cute GVHD [22,27,31,40]. Relapse was reported by
studies [22,31,38], but only 2 provided numerical
etails [22,31] (Table 5). Although sensitivity and sub-
roup analyses were planned, the small number of
tudies limited the number of analyses.
rimary Outcome: VOD
The results of using UA alone as prophylaxis in
SCT compared with no treatment were pooled from
randomized studies and demonstrated a RR of 0.34
95% CI, 0.17-0.66; Figure 2). The single study by
ark et al [39] that compared combination of UA and
eparin with heparin alone did not demonstrate a
eneﬁt (RR, 0.82; 95% CI, 0.42-1.60). Similarly, a
tudy by Thornley et al [40] comparing the combina-
ion of multivitamins with UA showed no statistically
igniﬁcant beneﬁt (RR, 0.19; 95% CI, 0.03-1.35). A
andomized study by Essell et al [22] comparing UA
ith no treatment with a Jadad score 3 was signiﬁ-
ant (RR, 0.36; 95% CI, 0.15-0.90). No differences
ere found between studies which reported exclu-
ively on recipients of allogeneic HSCT versus
tudies of patients undergoint allogeneic and autol-
elevant clinical trials. VOD indicates veno-occlusive disease.gous HSCT (data not shown).
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J. Tay et al.210Publication bias was assessed using a funnel plot
hat compared the RR of HVOD with the standard
rror for each study (Figure 3). The funnel plot
howed no signiﬁcant asymmetry.
econdary Outcomes
Three of the 4 trials that reported on TRM com-
ared UA with no treatment, 2 of which were ran-
omized studies [22,31]. The pooled RR for the 2
andomized trials was 0.58 (95% CI, 0.35-0.95). Park
t al [39] compared the combination of UA and hep-
rin with heparin alone and reported an RR of 1.24
95% CI, 0.54-2.03; Figure 4).
Three studies reported OS. The pooled RR of
he 2 randomized controlled trials was 1.15 (95%
I, 0.94-1.41), whereas the historical controlled
tudy demonstrated an RR of 1.44 (95% CI, 1.09-
.89; Figure 4).
Four studies reported on acute GVHD. Two ran-
omized trials compared UA with no treatment. The
istorical controlled study by Thornley et al [40] eval-
ated combination therapy with UA versus no treat-
ent, and study by Essell et al [27] compared UA with
o treatment. The pooled RR for the 2 randomized
rials was 0.76 (95% CI, 0.53-1.09; Figure 4).
Relapse was reported in 3 studies, with complete
able 2. Study Quality Assessment Tool
Quality Assessment of Individual Trials
Essell et al
[27]
re the objectives of the study clearly stated? 
s the study design suitable/reasonable for the
objectives? 
ere the inclusion criteria clear? 
as a sample size calculation performed? NA
as the sample size justified by the authors? NA
ere all subjects accounted for? 
ere appropriate outcomes considered? 
as ethical approval obtained? 
as the study randomized? 
as the randomization described and appropriate? NA
as there adequate allocation concealment? NA
as the study double blinded? NA
as blinding described? NA
ere dropouts (if any) described? NA
as intention-to-treat analysis used? NA
re the outcomes clinically relevant? 
ere the outcomes clearly defined? 
re the baseline data adequately described? 
ere the groups comparable at baseline? 
re the results internal consistent? Numbers
add up? 
ere there side effects reported? 
re the data suitable for analysis? 
re the methods appropriate to the data? 
as the statistics correctly interpreted? 
re the authors’ conclusion justified? 
adad scores for randomized trials NA
A indicates not applicable; , yes; , no; NS, not stated.ata available from only 2 (Figure 4) [22,31]. Both dtudies with complete data were randomized and
ompared UA with no treatment. The pooled sum-
ary RR was 0.77 (95% CI, 0.46-1.31; Figure 4).
ISCUSSION
Our systematic review demonstrates that prophy-
actic UA signiﬁcantly reduces the proportion of
VOD in patients undergoing allogeneic HSCT
RR, 0.34; 95% CI, 0.17-0.66). The reduction of
VOD also resulted in lower TRM (RR, 0.36; 95%
I, 0.35-0.95), although a reduction in OS was not
bserved (RR, 1.15; 95% CI, 0.94-1.41). A trend to-
ard lower rates of disease relapse (RR, 0.77; 95% CI,
.45-1.31) and acute GVHD (RR, 0.76; 95% CI, 0.53-
.09) was observed but did not reach statistical signif-
cance. Increased number of patients may be required
o achieve sufﬁcient power to draw conclusions re-
arding these important clinical events. Further, de-
pite the beneﬁcial prophylactic effects of UA in at-
enuating short-term toxicity including HVOD and
RM, later outcomes such as relapse and OS are
nﬂuenced by factors that extend beyond the early
egimen-related toxicities [41].
Our review identiﬁed relatively few controlled
tudies with modest samples; however we were able to
ll et al
22]
Ohashi et al
[38]
Park et al
[39]
Ruutu et al
[31]
Thornley et al
[40]
    
    
    
    
  NA  NA
    
    
 NS  NS 
    
    NA
 NS NS NS NA
    NA
 NA NA NA NA
A    NA
A    NA
    
    
    
    
    
    
    
    
    
    
3 2 3 2 NAEsse
[
N
Nemonstrate a favorable clinical effect of UA on re-
Table 3. Characteristics of Included Studies
Patients, n Age (y) Gender (% Male) Conditioning Regimen Intervention
Study/
Country
Centers,
n/Study
Design
Experimental
Arm
Control
Arm
Experimental
Arm
Control
Arm
Experimental
Arm
Control
Arm
Experimental
Arm
Control
Arm
Experimental
Arm
Control
Arm
Essell et al
[27]/USA
1/non-RCT
(historical
control)
28 22 Mean 33.2
(range 11-57)
Mean 39
(range 19-61)
77% 61% Bu/Cy Bu/Cy 600 mg (<90 kg),
900 mg (>90
kg) OD PO
from day 7
to day 80
None
Essell et al
[22]/USA
1/RCT 32 35 Mean 38
(range 22-56)
Mean 37
(range 21-56)
63% 63% Bu/Cy Bu/Cy 600 mg (<90 kg),
900 mg (>90
kg) OD PO
started before
HSCT to day
80
None
Ohashi et al
[38]/Japan
9/RCT 67 65 Mean 34.5 Mean 35.7 60% 46% Chemotherapy
based 23 (Bu/Cy
and Bu/VP16, 18);
chemotherapy 
TBI 34;
chemotherapy 
TLI 10
Chemotherapy
based 18 (Bu/Cy
and Bu/VP 12);
chemotherapy 
TBI 37;
chemotherapy 
TLI 10
600 mg OD PO
from day 21
to day 80
None
Park et al
[39]/Korea
1/RCT 82 83 Median 39 Median 38 50% 48% Variety used: with
TBI 27, with Bu/
Cy 13, others 42
Variety used: with
TBI 31, with Bu/
Cy 16, others 36
900 mg OD PO
from day 1
to day 30 and
heparin 5 IU/
(kg · h)
Heparin 5
IU/(kg · h)
Ruutu et al
[31]/Finland
3/RCT 123 119 Median 38
(range 5-59)
Median 40
(range 1-58)
50% 43% TBI based 112,
chemotherapy
only 11, Bu 6,
ATG 56
TBI based 107,
chemotherapy
only 12, Bu 11,
ATG 51
12 mg/(kg · d)
PO from day
1 to day 30
None
Thornley et al
[40]/USA
1/non-RCT
(historical
control)
37 131 Median 8
(range 0.7-19)
Median 8
(range 0.4-22)
NR NR TBI based 33 TBI based 113 15 mg/(kg · d)
PO from day
1 to day 27,
folinic acid,
vitamin E, and
parenteral
nutrition
None
RCT indicates randomized controlled trial; Bu/Cy, busulfan/cyclophosphamide; TBI, total body irradiation; TLI, total lymphoid irradiation; HSCT, hematopoietic stem cell transplantation; OD, once
daily; PO, orally; VP16, etoposide; ATG, antithymocyte globulin; NR, not reported.
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J. Tay et al.212ucing the incidence of HVOD by pooling the results
f the 3 randomized trials comparing UA with no
reatment. The results of the randomized trial by Park
t al [39] were not included in the overall summary
easurement of results from the other randomized
ontrolled trials concerning our primary outcome.
e could not substantiate an assumption of no inter-
ction between the combination of UA and heparin in
he experimental arm of the study by Park et al,
eading us to exclude these results from the pooled
stimates obtained from the other studies. If one in-
ludes the results from Park et al in the pooled esti-
ate, the reduction in HVOD remains signiﬁcant
data not shown). The beneﬁcial effects of UA on
educing HVOD appear to also contribute to im-
roved rates of TRM.
The study populations from the studies included
n our systematic review are heterogeneous in terms of
he conditioning chemotherapy and the dosing of UA.
n particular, the studies by Essell et al used predom-
nantly busulfan and cyclophosphamide as condition-
ng agents, whereas the remainder of studies used a
ariety of regimens, largely excluding busulfan. De-
pite the differences, the test for heterogeneity is not
igniﬁcant (P  .002) and the I2 is 0% for our primary
utcome derived from the 3 randomized studies com-
aring UA with no treatment, suggesting that overall
eterogeneity is low and exerting minimal effect on
he pooled estimate of HVOD prevention using UA.
Busulfan is commonly employed as conditioning
herapy in patients undergoing myeloablative alloge-
eic HSCT and is associated with increased risk of
eveloping HVOD [42]. This likely contributes to the
ncreased proportion of patients in the control arm of
he studies by Essell et al [22,35] who developed
VOD as busulfan was used in all patients. In addi-
ion, it is worth noting that the deﬁnition of HVOD
sed by Essell et al may include patients with less
evere disease, thus contributing to the larger propor-
ion of HVOD in the control arm. The baseline inci-
ence of HVOD in control arms of the other studies
ncluded in our analysis is appreciably lower. Patients
ho received busulfan as part of the conditioning
egimen in the studies by Ohashi et al and Ruutu et al
ere 20% and 10%, respectively (Table 3). More-
ver, we suggest the relative beneﬁcial effects of UA
ay be similar regardless of baseline risk (Figure 5),
ndicating that UA may beneﬁt a heterogeneous group
f patients.
The use of pharmacologic prophylaxis to reduce
VOD and the toxicity of transplantation must be
onsidered in concert with the changing risk factors
or HVOD. With the appreciation that busulfan is a
isk factor for HVOD, serum busulfan levels can be
easured to guide adjustments in dosing, thereby po-
entially reducing toxicities associated with variable
bioavailability and pharmacokinetics observed be-Ta Es
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ion centers have adopted the use of intravenous
usulfan and closer monitoring of serum levels in an
ffort to reduce HVOD and other transplant-related
roblems [43-46]. Further, cyclophosphamide is asso-
iated with HVOD and it has been suggested that
onitoring and subsequent dosing of cyclophospha-
ide and its metabolites in context of cyclophospha-
ide/total body irradiation regimens may be beneﬁ-
ial [47]. The studies identiﬁed by our review only
ncluded patients undergoing myeloablative alloge-
eic HSCT. However, reduced intensity prepara-
ive regimens are increasingly used in allogeneic
able 5. Deﬁnitions and Reported Outcomes of Included Studies
Study Follow-up Duration HVOD Definitio
ssell et al [27] NR McDonald/Seattle cri
ssell et al [22] Mean 42 mo <30 d after HSCT an
3: bilirubin >3 mg/
painful hepatomeg
accumulation (asci
>5% weight gain)
hashi et al [38] Median 182 d 2 of 3: bilirubin >2.0
painful hepatomeg
accumulation (asci
>2% weight gain)
ark et al [39] 100 d Modified Seattle crit
uutu et al [31] >1 y McDonald/Seattle cri
Jones/Baltimore cr
hornley et al [40] >4 y NR
VOD indicates hepatic veno-occlusive disease; VOD, veno-occ
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft
not reported;  yes; , no.
McDonald criteria: 30 days after HSCT, jaundice, hepatomegaly
21 days after HSCT, bilirubin 2 mg/dL, and 2 of the follo
Modiﬁed Seattle criteria:20 days after HSCT, occurrence of 2
quadrant pain of liver origin, unexplained weight gain (2% of
igure 2. Forest plots of (A) hepatic veno-occlusive disease (primary
isease from randomized trials. CI indicates conﬁdence interval; RR, relatSCT. The risk of HVOD in this setting may be
imilarly reduced [48].
There are other limitations in this review worth
ecognition. Although our review incorporated data
hat were available from published reports regarding
ur primary outcome, the investigators were not con-
acted to obtain unreported data on secondary out-
omes. In addition, we acknowledge that other pro-
hylactic agents have been used in the prevention of
VOD. However, studies combining other agents
ith UA were captured by, as evidenced by the inclu-
ion of the trial by Park et al. Interestingly, a retro-
pective cohort study from the European Group for
Reported Outcomes
VOD TRM OS aGVHD cGVHD Relapse
     
id
     
,
id
     Yes, but specifics
not provided
     
r      
     
disease; TRM, transplant-related mortality; OS, overall survival;
-host disease; HSCT, hematopoietic stem cell transplantation; NR,
ht upper quadrant pain, ascites, and/or weight gain. Jones criteria:
tender hepatomegaly, ascites, or weight gain 5% from baseline.
ollowing events: bilirubin2 mg/dL, hepatomegaly, or right upper
e body weight) because of ﬂuid accumulation.
me) in all studies and (B) pooled estimate of hepatic veno-occlusiven*
teria
d 2 of
dL,
aly, flu
tes or
mg/dL
aly, flu
tes or
eria
teria o
iteria
lusive
-versus
and rig
wing:
of the foutco
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J. Tay et al.214lood and Marrow Transplantation [2] and a recent
ystematic review of prophylactic heparin in patients
ndergoing allogeneic HSCT did not demonstrate a
eneﬁt in terms of HVOD (pooled RR, 0.90; 95% CI,
.62-1.29) [13]. Further, the potential for increased
isk of bleeding in these high-risk patients remains a
Figure 3. Funnel plot to assess publication bia
igure 4. Forest plots of secondary outcomes. aGVHD indicates ac
CT, randomized controlled trial; RR, relative risk; TRM, transplant-reloncern with agents that inﬂuence the coagulation
ystem.
There has been much excitement around the use
f deﬁbrotide, a novel agent that has shown promise in
he management of HVOD. Although its exact mech-
nism of action is unknown, its clinical effect may be
hepatic veno-occlusive disease as an outcome.
ft-versus-host disease; CI, conﬁdence interval; OS, overall survival;ute gra
ated mortality; UA, ursodeoxycholic acid.
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ndothelial level by causing endothelial release of tis-
ue plasminogen activator [49], upregulation of the
elease of nitric oxide, prostaglandins I2 and E2 [50],
hrombomodulin [51], decreased release of plasmino-
en activator inhibitor [52], stimulation of adenosine
eceptor [53], decreased thrombin generation, and de-
reased tissue factor activity and endothelin activity
54,55]. There have been numerous encouraging re-
orts on its beneﬁcial effects alone [56-62] or in com-
ination with other agents [61,63-65] in the therapy of
stablished HVOD. These studies were reviewed in a
ecent publication [55]. In contrast, the prophylactic
se of deﬁbrotide is less well studied, with no pub-
ished randomized trials supporting its use. The larg-
st published prophylactic trial was a single-institution
tudy that compared 52 consecutive patients undergo-
ng HSCT for hematologic malignancies with 52 his-
orical controls [66]. All patients received heparin pro-
hylaxis, with the experimental arm also receiving
eﬁbrotide. The investigators were able to demon-
trate that the combined treatment of deﬁbrotide and
eparin reduced maximum bilirubin levels, the pro-
ortion of patients with HVOD, improved event-free
urvival, and trend toward improved 100-day mortal-
ty. We are aware of only 1 ongoing randomized trial
hat was conducted in the pediatric population to
ddress deﬁbrotide prophylaxis for HVOD (Clinical-
rials.gov Identiﬁer: NCT00272948).
In summary, the favorable tolerance and ease of
dministering UA appear to be coupled with reductions
n HVOD and TRM, as suggested in this systematic
eview. We suggest that UA should be considered as
ffective pharmacologic prevention of HVOD in adult
atients undergoing allogeneic HSCT.
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